CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment

Stem Cells

Volumn 32, Issue 1, 2014, Pages 145-156

  Kinugasa, Yumi ^a   Matsui, Takahiro ^a,b   Takakura, Nobuyuki ^a,c  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Cancer associated fibroblasts; CD44; Tumor microenvironment; Tumor stroma

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; HERMES ANTIGEN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER STEM CELL; CARCINOGENESIS; COCULTURE; CONTROLLED STUDY; FEMALE; FIBROBLAST; IN VITRO STUDY; MOUSE; NONHUMAN; TUMOR MICROENVIRONMENT; WILD TYPE;

CANCER ASSOCIATED FIBROBLASTS; CD44; TUMOR MICROENVIRONMENT; TUMOR STROMA;

ANIMALS; ANTIGENS, CD44; APOPTOSIS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; FEMALE; FIBROBLASTS; HT29 CELLS; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS; NEOPLASTIC STEM CELLS; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 84891757812     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1556     Document Type: Article

References (41)

1. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392-401.
2. Orimo A, Weinberg RA. Heterogeneity of stromal fibroblasts in tumors. Cancer Biol Ther 2007;6:618-619.
3. Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth-Bystanders turning into key players. Curr Opin Genet Dev 2009;19:67-73.
4. Sugimoto H, Mundel TM, Kieran MW et al. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 2006;5:1640-1646.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144: 646-674.
6. Pietras K, Ostman A. Hallmarks of cancer: Interactions with the tumor stroma. Exp Cell Res 2010;316:1324-1331.
7. Song S, Ewald AJ, Stallcup W et al. PDGFRbeta1 perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 2005;7:870-879.
8. Potenta S, Zeisberg E, Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. Br J Cancer 2008;99: 1375-1379.
9. Zeisberg EM, Potenta S, Xie L et al. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 2007;67:10123-10128.
10. Barrett LE, Granot Z, Coker C et al. Selfrenewal does not predict tumor growth potential in mouse models of high-grade glioma. Cancer Cell 2012;21:11-24.
11. Clevers H. The cancer stem cell: Premises, promises and challenges. Nat Med 2011;17:313-319.
12. Fan X, Ouyang N, Teng H et al. Isolation and characterization of spheroid cells from the HT29 colon cancer cell line. Int J Colorectal Dis 2011;26:1279-1285.
13. Huang EH, Hynes MJ, Zhang T et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009;69: 3382-3389.
14. Lin L, Liu A, Peng Z et al. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res 2011;71: 7226-7237.
15. Moreb JS. Aldehyde dehydrogenase as a marker for stem cells. Curr Stem Cell Res Ther 2008;3:237-246.
16. Nagahama Y, Ueno M, Miyamoto S et al. PSF1, a DNA replication factor expressed widely in stem and progenitor cells, drives tumorigenic and metastatic properties. Cancer Res 2010;70:1215-1224.
17. Ueno M, Itoh M, Kong L et al. PSF1 is essential for early embryogenesis in mice. Mol Cell Biol 2005;25:10528-10532.
18. Ueno M, Itoh M, Sugihara K et al. Both alleles of PSF1 are required for maintenance of pool size of immature hematopoietic cells and acute bone marrow regeneration. Blood 2009;113:555-562.
19. Matsui T, Kinugasa Y, Tahara H et al. Possible role of mural cell-covered mature blood vessels in inducing drug resistance in cancer-initiating cells. Am J Pathol 2013;182: 1790-1799.
20. Mikecz K, Brennan FR, Kim JH et al. Anti-CD44 treatment abrogates tissue oedema and leukocyte infiltration in murine arthritis. Nat Med 1995;1:558-563.
21. Screaton GR, Bell MV, Jackson DG et al. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992;89:12160-12164.
22. Gunthert U, Hofmann M, Rudy W et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13-24.
23. Zoller M. CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011;11:254-267.
24. Ishimoto T, Nagano O, Yae T et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(2) and thereby promotes tumor growth. Cancer Cell 2011;19:387-400.
25. Ponta H, Sherman L, Herrlich PA. CD44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003;4:33-45.
26. Kinugasa Y, Takakura N. Monoclonal antibody selectively recognizing murine but not human CD44. Hybridoma (Larchmt) 2012;31: 262-266.
27. Presta L G, Chen H, O'connor S J, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
28. Franklin WA, Christison WH, Colley M et al. In situ distribution of the beta-subunit of platelet-derived growth factor receptor in nonneoplastic tissue and in soft tissue tumors. Cancer Res 1990;50:6344-6348.
29. Wilson W R, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011;11: 393-410.
30. Gupta PB, Chaffer C L, Weinberg RA. Cancer stem cells: Mirage or reality? Nat Med 2009;15:1010-1012.
31. Mohyeldin A, Garzon-Muvdi T, Quinones-Hinojosa A. Oxygen in stem cell biology: A critical component of the stem cell niche. Cell Stem Cell 2010;7:150-161.
32. Calabrese C, Poppleton H, Kocak M et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11:69-82.
33. Naito H, Takara K, Wakabayashi T et al. Changes in blood vessel maturation in the fibrous cap of the tumor rim. Cancer Sci 2012;103:433-438.
34. Jeon ES, Moon HJ, Lee MJ et al. Cancerderived lysophosphatidic acid stimulates differentiation of human mesenchymal stem cells to myofibroblast-like cells. Stem Cells 2008;26:789-797.
35. Mishra PJ, Mishra PJ, Humeniuk R et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 2008;68:4331-4339.
36. Ishii G, Sangai T, Oda T et al. Bonemarrow-derived myofibroblasts contribute to the cancer-induced stromal reaction. Biochem Biophys Res Commun 2003;309:232-240.
37. Direkze NC, Hodivala-Dilke K, Jeffery R et al. Bone marrow contribution to tumorassociated myofibroblasts and fibroblasts. Cancer Res 2004;64:8492-8495.
38. Petersen OW, Nielsen HL, Gudjonsson T et al. Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am J Pathol 2003;162:391-402.
39. Kojima Y, Acar A, Eaton EN et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci USA 2010;107: 20009-20014.
40. Quante M, Tu SP, Tomita H et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011;19: 257-272.
41. Crawford Y, Ferrara N. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol Sci 2009;30:624-630.